Trial Profile

A Single-center, Single-dose, Randomized, Open-label, Two-cycle, Crossover Study of Bioequivalence of Famitinib Malate Capsules of Different Specifications Taken Orally in Healthy Subjects Under Fasting Condition

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Famitinib (Primary)
Indications Biliary cancer; Breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal stromal tumours; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Thyroid cancer; Triple negative breast cancer; Urogenital cancer
Focus Pharmacokinetics
Sponsors Jiangsu Hengrui Medicine Co.

17 May 2023 Status changed from active, no longer recruiting to completed.
20 May 2022 Status changed from not yet recruiting to active, no longer recruiting.
25 Apr 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com